Two preclinical immuno‑oncology advances surfaced this week. A Nature Communications study showed Boron Neutron Capture Therapy (BNCT) can preserve immune cell integrity while eliciting anti‑tumor immunity in mouse models, suggesting a way to combine targeted radiation chemistry with immune activation. Separately, a Nature Biomedical Engineering paper reported engineered bacterial outer membrane vesicles (OMVs) that, when combined with CAR‑T cells, enhanced infiltration and anti‑tumor responses in solid‑tumor models—an approach aimed at overcoming CAR‑T barriers in solid cancers.